Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts have also weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $6.60 price target on […]

Leave a Reply

Your email address will not be published.

Previous post OptimumBank (NASDAQ:OPHC) Research Coverage Started at StockNews.com
Next post Ski Wednesday: Tips for the senior skier